Psychiatry Editorial
  • Home
  • News
  • About
  • Contact

MDLIVE Providing Free Online Health Consultations to California Residents Impacted by Wildfires

Press Releases MDLive, MedTech, Telemedicine

24/7 Access to Medical and Health Professionals Available as Part of MDLIVECares Initiative

Sunrise, Fla., Nov. 16, 2018 (GLOBE NEWSWIRE) — MDLIVE Inc., which is focused on delivering high-quality, convenient, cost-effective virtual medical, dermatological and behavioral healthcare, today announced it is providing individuals and families impacted by California’s wildfires with free online health visits through the MDLIVECares national crisis relief program. This offering is available from Nov. 16 through Nov. 29 and reflects the company’s commitment to ensuring people have uninterrupted access to medical and health professionals, especially during times of crisis.

California residents impacted by the wildfires can call a dedicated MDLIVE hotline at 888-959-9516 and provide the code Cali25 to schedule their initial consultations. Consultations after that call will be conducted via telephone or video, enabling individuals to select the platform most convenient for their individual case. This offering is available via MDLIVE’s online medical network for the diagnosis and treatment of common health problems as well as non-emergency dermatological ailments and behavioral issues.

“As the California wildfires continue to devastate communities and displace families and individuals from their homes, we are working quickly to help residents maintain access to care when needed,” said Rich Berner, Chief Executive Officer of MDLIVE. “It is our mission to assure the residents of California that their healthcare needs will be met during this challenging time, and we are committed to doing what we can to provide support through our comprehensive online network of care.”

About MDLIVE
MDLIVE was founded on the principle that healthcare should be simple, fast and uncomplicated. Since 2009, the company has remained steadfast in its mission to deliver high-quality, convenient and cost-efficient care to patients and organizations across the United States. Through MDLIVE’s comprehensive telehealth platform, millions of people are empowered with 24/7/365 access to the company’s network of board-certified internists, family practitioners, pediatricians, emergency room specialists, dermatologists, psychiatrists, and counselors. The company constantly looks to break scientific and industry barriers by pairing cutting-edge technologies, automation philosophies and evidence-based content with a vision to improve both efficiency and quality. At the same time, Sophie, MDLIVE’s personal health assistant, aims to improve the consumer experience via a multi-channel approach that can evolve quickly as new technologies become available. MDLIVE’s HIPAA- and PHI-compliant, cloud-based platform gives registered users access to virtual consultations through secure online video, phone or the MDLIVE app.

To learn more about how MDLIVE is using telehealth innovations to improve the delivery of healthcare, visit www.MDLIVE.com, download our mobile app or text “Sophie” to MLIVE (635483) to register.

Stay connected with MDLIVE and see its latest news on social media. Follow MDLIVE on Twitter, Facebook and YouTube.

SOURCE: MDLIVE

Related Posts

Press Releases

Teladoc Health to Acquire InTouch Health

Press Releases

Vivante Health Snags DebraAnn Braun as Chief Technology Officer

Press Releases

Dr. Jason Hallock Joins SOC Telemed as Chief Medical Officer

Featured News

  • Teladoc Health to Acquire InTouch Health
  • Vivante Health Snags DebraAnn Braun as Chief Technology Officer
  • Dr. Jason Hallock Joins SOC Telemed as Chief Medical Officer
  • Change Healthcare Unveils API & Services Connection, a Marketplace to Accelerate Innovation in Healthcare
  • Gemelli Hospital on Track to Become More Digitized for Better Patient Management

Elevator Talks: New Drugs

  • Alkermes Initiates Rolling Submission of ALKS 5461 New Drug Application for Major Depressive Disorder
  • Alkermes Announces Positive Preliminary Topline Results From Phase 3 Antipsychotic Efficacy Study of ALKS 3831 for Treatment of Schizophrenia
  • Alkermes Announces Initiation of Study 217 for ALKS 5461 for Treatment of Major Depressive Disorder
  • Alkermes Announces Initiation of Phase 3 Study of ALKS 3831 in Young Adult Patients
  • FDA Approves Two-Month ARISTADA® for Treatment of Schizophrenia
Psychiatry Editorial
Copyright © PhysicianEditorial.com
All Rights Reserved!